Huntingtin in health and disease

Journal of Clinical Investigation

Volumn 111, Issue 3, 2003, Pages 299-302

  Young, Anne B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CASPASE INHIBITOR; CREATINE; GLUTAMATE RECEPTOR ANTAGONIST; HUNTINGTIN; IDEBENONE; LAMOTRIGINE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; REMACEMIDE; RILUZOLE; SCAVENGER;

BRAIN FUNCTION; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DNA MICROARRAY; DRUG TARGETING; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; TRANSGENIC MOUSE;

EID: 0037316787     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI17742     Document Type: Review

References (65)

1. Gusella, J.F., et al. 1983. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 306:234-238.
2. 1993. A novel gene containing a trinucleotide repeat that is unstable in Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 72:971-983.
3. Young, A.B. 1998. Huntington's disease and other trinucleotide repeat disorders. In Molecular neurology. J.B. Martin, editor. Scientific American Medicine. New York, New York, USA. 35-54.
4. Rubinsztein, D.C., et al. 1996. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet. 59:16-22.
5. Snell, R.G., et al. 1993. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4:393-397.
6. MacDonald, M.E., et al. 1993. Garnetic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Genet. 30:982-986.
7. Faber, P.W., et al. 1998. Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet. 7:1463-1474.
8. Wellington, C.L., et al. 1998. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273:9158-9167.
9. Landwehrmeyer, G.B., et al. 1995. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann. Neurol. 37:218-230.
10. DiFiglia, M., et al. 1995. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 14:1075-1081.
11. Ferrante, R.J., et al. 1997. Heterogeneous topographic and cellular distribution of Huntington expression in the normal human neostriatum. J. Neurosci. 17:3052-3063.
12. Velier, J., et al. 1998. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152:34-40.
13. Li, X.J., et al. 1995. A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 378:398-402.
14. Kalchman, M.A., et al. 1997. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat. Genet. 16:44-53.
15. Burke, J.R., et al. 1996. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:347-350.
16. Sun, Y., Savanenin, A., Reddy, P.H., and Liu, Y.F. 2001. Polyglutamine-expanded huntingtin promotes sensirization of N-Methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276:24713-24718.
17. Duyao, M.P., et al. 1995. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 269:407-410.
18. O'Kusky, J.R., Nasir, J., Cicchetti, F., Parent, A., and Hayden, M.R. 1999. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Res. 818:468-479.
19. Dragatsis, I., Efstrariadis, A., and Zeitlin, A. 1998. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development. 125:1529-1539.
20. Dragatsis, I., Levine, M.S., and Zeitlin, S. 2000. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26:300-306.
21. Rigamonti, D., et al. 2000 Wild-type huntingtin protects from apoptosis upstream ofcaspase-3. J. Neurosci. 20:3705-3713.
22. Zuccato, C., et al. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 293:493-498.
23. Leavitt, B.R., et al. 2001. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 68:313-324.
24. Persichetti, F., et al. 1996. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol. Dis. 3:183-190.
25. Trottier, Y., et al. 1995. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 10:104-110.
26. DiFiglia, M., et al. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1990-1993.
27. Sapp, E., et al. 1997. Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 42:604-612.
28. Davies, S.W., et al. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:537-548.
29. Reiner, A., et al. 1988. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA. 85:5733-5737.
30. Albin, R.L., et al. 1990. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl. J. Med. 322:1293-1298.
31. Glass, M., Dragunow, M., and Faull, R.L. 2000. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 97:505-519.
32. Albin, R.L., Reiner, A., Anderson, K.D., Penney, J.B., and Young, A.B. 1990. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidityakinesia. Ann. Neurol. 27:357-365.
33. Roizin, L., Stellar, S., and Liu, J.C. 1979. Neuronal nuclear-cytoplasmic changes in Huntington's chorea: electron microscope investigations. In Advances in neurology. Volume 23. T.N. Chase, N.S. Wexler, and A. Barbeau, editors. Raven Press. New York, New York, USA. 95-122.
34. Mangiarini, L., et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:493-506.
35. Kim, M., et al. 1999. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19:964-973.
36. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:55-66.
37. Scherzinger, E., et al. 1997. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90:549-558.
38. Huang, C.C., et al. 1998. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24:217-233.
39. Perutz, M.F., Johnson, T., Suzuki, M., and Finch, J.T. 1994. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA. 91:5355-5358.
40. Green, D.R. 1999. Harm's way: polyglutamine repeats and the activation of an apoptotic pathway. Neuron. 22:416-417.
41. Hollenbach, B., et al. 1999. Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:991-994.
42. Schilling, G., et al. 1999. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:397-407.
43. Reddy, P.H., et al. 1999. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1035-1045.
44. Hodgson, J.G., et al. 1999. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23:181-192.
45. Ordway, J.M., et al. 1997. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 91:753-763.
46. Yamamoto, A., Lucas, J.J., and Hen, R. 2000. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101:57-66.
47. Cha, J.-H.J., et al. 1998. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad Sci. USA. 95:6480-6485.
48. Luthi-Carter, R., et al. 2000. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9:1259-1271.
49. Ferrante, R.J., et al. 2000. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20:4389-4397.
50. Ona, V.O., et al. 1999. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399:263-267.
51. Carter, R.J., Hunt, M.J., and Morton, A.J. 2000. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 15:925-937.
52. Chen, M., et al. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6:797-801.
53. Levine, M.S., et al. 1999 Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58:515-532.
54. Hansson, O., et al. 1999. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA. 96:8727-8732.
55. Sipione, S., and Cattaneo, E. 2001. Modeling Huntington's disease in cells, flies, and mice. Mol. Neurobiol. 23:21-51.
56. Faber, P.W., Alter, J.R., MacDonald, M.E., and Hart, A.C. 1999. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. USA. 96:179-184.
57. Steffan, J.S., et al. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 413:739-743.
58. Satyal, S.H., et al. 2000. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA. 97:5750-5755.
59. Li, S.H., Cheng, A.L., Li, H., and Li, X.J. 1999. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J. Neurosci. 19:5159-5172.
60. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D., and Housman, D 1999. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. USA. 96:11404-11409.
61. Steffan, J.S., et al. 2000. The Huntington's disease protein interacts with p53 and CBP and represses transcription. Proc. Natl. Acad. Sci. USA. 97:6763-6768.
62. Kieburtz, K., et al. 1996. Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord. 11:136-142.
63. Kieburtz, K. 1999. Antiglutamate therapies in Huntington's disease. J. Neural Transm. Suppl. 55:97-102.
64. Schilling, G., Coonfield, M.L., Ross, C.A., and Borchelt, D.R. 2001. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315:149-153.
65. 2001. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 57:397-404.